Halo Neuroscience was positioned in the consumer neurostimulation segment, using tDCS to enhance motor learning and athletic performance rather than treating disease. Its acquisition and product focus placed it closer to performance technology than clinical neurotherapy, limiting regulatory complexity but also constraining medical defensibility.